PHAR · Pharming Group N.V. · Metrics
$12.13
-0.13 (-1.06%)
At close · Oct 29
Return incl. dividend (before tax)
Q3 2026 earnings call transcript
Market Cap
$859.95M
Shares
70.78M
Volume · Oct 29
12.43K
Avg daily vol (3M)
25.01K
PHAR metrics
59 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$12.13
Market cap
$859.95M
Price action
20 metricsPrice change (1W)
+13.7%
Price change (30D)
+21.2%
Price change (3M)
+12.8%
Price change (6M)
-26.6%
Price change (YTD)
-31.4%
Price change (1Y)
-9.5%
Trailing year
Price change (5Y)
+34.8%
52-week high
$21.18
52-week low
$9.11
Change from 52-week high
-42.7%
Change from 52-week low
+33.2%
Annualized volatility
63.4%
Annualized volatility (3M)
56.2%
Beta
1.0
RSI (14D)
69.3
Price vs SMA 50
+13.3%
Price vs SMA 200
-12.2%
Avg volume (3M)
25,006
Relative volume
0.5
Average dollar volume
$275,161
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
70.78M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.1
reciprocal yield 32.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-10-27
Profitability
9 metricsGross margin
87.9%
Operating margin
6.9%
Trailing 12 months
Net margin
0.8%
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+26.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.1%
Year over year · more shares
Revenue CAGR (3Y)
+22.3%
Revenue CAGR (5Y)
+12.1%
EPS CAGR (3Y)
-40.5%
EPS CAGR (5Y)
-40.8%
FCF CAGR (3Y)
+36.8%
FCF CAGR (5Y)
-7.3%
Quality
14 metricsReturn on equity
1.0%
Return on assets
0.6%
Debt / equity
0.4
Current ratio
2.6
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
2.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$81.05M
Latest balance sheet
Cash & equivalents
$145.31M
Total assets
$499.96M
Total debt
$98.06M
Cash flow & spend
7 metricsOperating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
16
13F filer change QoQ
+3
Institutional ownership
0.1%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+12.0%
Holder tenure
8.5
Price vs estimated holder cost
-7.4%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.0%
Short interest
3 metricsShort interest
0.0%
Latest settlement · 1.5 days to cover
Days to cover
1.5d
Short-squeeze score
29 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—